Showing 5271-5280 of 5689 results for "".
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging/2476720/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- SparingVision Awarded €2.5 Million at EIC Accelerator Programhttps://modernod.com/news/sparingvision-awarded-e2-5-million-at-eic-accelerator-program/2476715/SparingVision announced that it has been awarded non-dilutive funding of €2.5 million to fund research into retinitis pigmentosa therapies. SparingVision submitted a winning proposal for the European EIC Accelerator (SME instrument phase 2) program. The funding will help speed up SparingVi
- Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-submits-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease/2476716/Horizon Therapeutics announced that it has submitted a biologics license application (BLA) to the FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has breakthrough therapy, orphan drug and fast track designations from the FDA. H
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- Bausch + Lomb Announces US Launch Of Ocuvite Eye Performance Vitaminshttps://modernod.com/news/bausch-lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins/2476714/Bausch + Lomb announced the US launch of Ocuvite Eye Performance vitamins, which were formulated with seven nutrients that help strengthen the macula. The nutrients protect the eye from stressors such as sun light and blue light emitted from digital devices. These nutrients include lutein
- Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-license-agreement-with-aura-biosciences-for-suprachoroidal-space-microinjector/2479566/Clearside Biomedical announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choro
- ProQR: RNA Therapy Has Potential to Restore Vision in Patients With Usher Syndromehttps://modernod.com/news/proqr-rna-therapy-has-potential-to-restore-vision-in-patients-with-usher-syndrome/2479570/Usher syndrome is an inherited retinal degeneration that affects hearing, balance, and vision. Usher syndrome caused by USH2A mutations is one of the most common causes of retinitis pigmentosa (RP) with syndromic features. Currently there is no treatment for the sensory deficits caused by Usher s
- EyeSouth Establishes Presence in Alabama Through Affiliation with Montgomery Eye Physicianshttps://modernod.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/EyeSouth Partners has announced that it has completed an affiliation with Montgomery Eye Physicians and Prescription Eyewear. The affiliation will be EyeSouth’s first in Alabama. Terms of the deal were not disclosed. EyeSouth is an eye care-focused management services organization.
- Small Percentage of Ophthalmologists Perform Large Proportion of Intravitreal Anti-VEGF Injectionshttps://modernod.com/news/small-percentage-of-ophthalmologists-perform-large-proportion-of-intravitreal-anti-vegf-injections/2476712/Three percent of ophthalmologists perform 17% to 31% of all anti-vascular endothelial growth factor (VEGF) injections in the U.S., depending on the agent used, according to new findings, as reported by Reuters. “More important